{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:42Z","timestamp":1793755062726,"version":"4.6.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.revmed.2013.12.003","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T11:15:29Z","timestamp":1389870929000},"page":"126-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Traitement de la maladie de Beh\u00e7et"],"prefix":"10.1016","volume":"35","author":[{"given":"C.","family":"Comarmond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.revmed.2013.12.003_bib0005","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"issue":"8697","key":"10.1016\/j.revmed.2013.12.003_bib0010","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012\u00a0revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.12.003_bib0020","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27\u00a0countries on the sensitivity and specificity of the new criteria","author":"Davatchi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.revmed.2013.12.003_bib0025","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.24642","article-title":"HLA-B51\/B5\u00a0and the risk of Beh\u00e7et's disease: a systematic review and meta-analysis of case-control genetic association studies","volume":"61","author":"De Menthon","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0030","first-page":"259","article-title":"The high prevalence of HLA-B5\u00a0in Beh\u00e7et's disease","volume":"30","author":"Yazici","year":"1977","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/08830189709116843","article-title":"Pathogenic gene responsible for the predisposition of Beh\u00e7et's disease","volume":"14","author":"Mizuki","year":"1997","journal-title":"Int Rev Immunol"},{"issue":"9","key":"10.1016\/j.revmed.2013.12.003_bib0040","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.27568","article-title":"Mortality in Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.revmed.2013.12.003_bib0045","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2013.12.003_bib0050","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.revmed.2013.12.003_bib0055","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MD.0b013e3181dfca14","article-title":"Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis","volume":"89","author":"Hello","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.revmed.2013.12.003_bib0070","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-124-10-199605150-00005","article-title":"Successful treatment of Beh\u00e7et disease with pentoxifylline","volume":"124","author":"Yasui","year":"1996","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Dapsone in Beh\u00e7et's disease: a double-blind, placebo-controlled, cross-over study","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0080","first-page":"399","article-title":"A double-blind study of colchicine in Beh\u00e7et's disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0085","first-page":"1098","article-title":"Systemic interferon alpha 2b treatment in Beh\u00e7et's syndrome","volume":"21","author":"Hamuryudan","year":"1994","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0090","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369\u00a0patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0100","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/MCG.0b013e3182431d56","article-title":"Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease","volume":"46","author":"Jung","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.revmed.2013.12.003_bib0105","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/0-306-48382-3_118","article-title":"High dose methotrexate for ocular lesions of Beh\u00e7et's disease. Preliminary short-term results","volume":"528","author":"Davatchi","year":"2003","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/j.revmed.2013.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","article-title":"Infliximab for patients with neuro-Behcet's disease: case series and literature review","volume":"30","author":"Borhani Haghighi","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2013.12.003_bib0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/0-306-48382-3_117","article-title":"Low dose MTX for progressive neuro-Beh\u00e7et's disease. A follow-up study for 4\u00a0years","volume":"528","author":"Kikuchi","year":"2003","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.neurol.2011.09.006","article-title":"Neurological manifestations of Beh\u00e7et's disease: evaluation of 40\u00a0patients treated by cyclophosphamide","volume":"168","author":"Ait Ben Haddou","year":"2012","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.24393","article-title":"Cerebral venous thrombosis in Beh\u00e7et's disease","volume":"61","author":"Saadoun","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3\u00a0Pt 1","key":"10.1016\/j.revmed.2013.12.003_bib0130","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.42.3.614","article-title":"Cerebral venous thrombosis in Beh\u00e7et's disease: clinical study and long-term follow-up of 25\u00a0cases","volume":"42","author":"Wechsler","year":"1992","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00019052-200406000-00017","article-title":"Beh\u00e7et's syndrome and the nervous system","volume":"17","author":"Siva","year":"2004","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e3182428f49","article-title":"Spectrum of cardiac lesions in Beh\u00e7et disease: a series of 52\u00a0patients and review of the literature","volume":"91","author":"Geri","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.revmed.2013.12.003_bib0145","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/art.34450","article-title":"Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et's disease","volume":"64","author":"Desbois","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MD.0b013e3182428126","article-title":"Long-term outcome of arterial lesions in Beh\u00e7et disease: a series of 101\u00a0patients","volume":"91","author":"Saadoun","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387\u00a0patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.revmed.2013.12.003_bib0160","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/acr.20308","article-title":"Azathioprine in severe uveitis of Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9394(14)72840-5","article-title":"Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Beh\u00e7et's disease","volume":"118","author":"Whitcup","year":"1994","journal-title":"Am J Ophthalmol"},{"issue":"9278","key":"10.1016\/j.revmed.2013.12.003_bib0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.revmed.2013.12.003_bib0175","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0185","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","article-title":"A double-blind trial of depot corticosteroids in Beh\u00e7et's syndrome","volume":"45","author":"Mat","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0190","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0195","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et's disease","volume":"192","author":"Azizlerli","year":"1996","journal-title":"Dermatology (Basel)"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0205","first-page":"896","article-title":"Long term visual prognosis of patients with ocular Adamantiades-Beh\u00e7et's disease treated with interferon alpha-2a","volume":"35","author":"Krause","year":"2008","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.revmed.2013.12.003_bib0210","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et's disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.revmed.2013.12.003_bib0215","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et's uveitis refractory to conventional treatments","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Behcet's syndrome: effects on long-term prognosis","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2010.12.002","article-title":"High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease","volume":"41","author":"Henderson","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.revmed.2013.12.003_bib0230","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10067-006-0385-0","article-title":"Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Beh\u00e7et's disease","volume":"26","author":"Melillo","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0235","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000056324","article-title":"Multiple pulmonary arterial aneurysms in Beh\u00e7et's disease: clinical and radiologic remission after cyclophosphamide and corticosteroid therapy","volume":"69","author":"Akto\u011fu","year":"2002","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.2005.035410","article-title":"Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5\u00a0years of follow-up","volume":"65","author":"Maurer","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0245","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/ard.2006.056630","volume":"66","author":"Daikeler","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM200101043440121","article-title":"Autologous hematopoietic stem-cell transplantation for Beh\u00e7et's disease with pulmonary involvement","volume":"344","author":"Hensel","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.revmed.2013.12.003_bib0255","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/ard.2007.070227","article-title":"Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis","volume":"67","author":"Statkute","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0260","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et's disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et's disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"10.1016\/j.revmed.2013.12.003_bib0270","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0275","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bjophthalmol-2012-302515","article-title":"Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis","volume":"97","author":"Sakai","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0280","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"issue":"8","key":"10.1016\/j.revmed.2013.12.003_bib0290","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","article-title":"Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease","volume":"48","author":"Iwata","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.revmed.2013.12.003_bib0295","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0300","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","article-title":"Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial","volume":"29","author":"Al-Rayes","year":"2008","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0305","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0310","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10384-012-0182-z","article-title":"Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy","volume":"56","author":"Yoshida","year":"2012","journal-title":"Jpn J Ophthalmol"},{"issue":"9","key":"10.1016\/j.revmed.2013.12.003_bib0315","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/bjo.2010.194464","article-title":"Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy","volume":"95","author":"Keino","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0320","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/s10165-011-0585-6","article-title":"Good response to infliximab in a patient with deep vein thrombosis associated with Beh\u00e7et disease","volume":"22","author":"Yoshida","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0325","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double-blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0330","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Beh\u00e7et's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-009-1272-2","article-title":"Adalimumab treatment for life threatening pulmonary artery aneurysm in Beh\u00e7et disease: a case report","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.revmed.2013.12.003_bib0340","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/ibd.20869","article-title":"Intestinal Beh\u00e7et's disease: maintenance of remission with adalimumab monotherapy","volume":"15","author":"Ariyachaipanich","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0345","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","article-title":"Resistant Beh\u00e7et disease responsive to anakinra","volume":"149","author":"Botsios","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0350","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0355","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","article-title":"Tocilizumab treatment for neuro-Behcet's disease, the first report","volume":"114","author":"Shapiro","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"3\u00a0Suppl. 72","key":"10.1016\/j.revmed.2013.12.003_bib0360","first-page":"S73","article-title":"Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report","volume":"30","author":"Urbaniak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0365","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A case of Beh\u00e7et's disease treated with a humanized anti-interleukin-6\u00a0receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0370","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0375","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Beh\u00e7et's disease with rituximab","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RHU.0b013e318284735c","article-title":"Remission induction in a case of refractory beh\u00e7et disease with alemtuzumab","volume":"19","author":"Perez-Pampin","year":"2013","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.revmed.2013.12.003_bib0385","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et's disease following lymphocyte depletion by the anti-CD52\u00a0antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"3\u00a0Suppl. 4","key":"10.1016\/j.revmed.2013.12.003_bib0390","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et's syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0395","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Beh\u00e7et's disease","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum"},{"issue":"8647","key":"10.1016\/j.revmed.2013.12.003_bib0400","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0405","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1021227019915","article-title":"Long-term therapy with low dose cyclosporin A in ocular Beh\u00e7et's disease","volume":"105","author":"Ozdal","year":"2002","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0410","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Beh\u00e7et's disease","volume":"76","author":"S\u00fcll\u00fc","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0415","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","article-title":"Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy","volume":"106","author":"Kotake","year":"1999","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0420","first-page":"802","article-title":"[A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Beh\u00e7et's disease and allied conditions]","volume":"35","author":"Sakane","year":"1995","journal-title":"Ryumachi"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0425","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0430","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","article-title":"Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease","volume":"159","author":"Hirohata","year":"1998","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0435","first-page":"185","article-title":"Combination therapy with infliximab and methotrexate in recalcitrant mucocutaneous Beh\u00e7et disease","volume":"89","author":"Chan","year":"2012","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0440","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/s10165-010-0370-y","article-title":"Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero-Beh\u00e7et's disease","volume":"21","author":"Iwata","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"4\u00a0Suppl. 60","key":"10.1016\/j.revmed.2013.12.003_bib0445","first-page":"S94","article-title":"Successful treatment of leg ulcers in Beh\u00e7et's disease using adalimumab plus methotrexate after the failure of infliximab","volume":"28","author":"Atzeni","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0450","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000051781","article-title":"Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Beh\u00e7et's disease","volume":"203","author":"Adler","year":"2001","journal-title":"Dermatology (Basel)"},{"issue":"4\u00a0Suppl. 67","key":"10.1016\/j.revmed.2013.12.003_bib0455","first-page":"S64","article-title":"Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Beh\u00e7et's disease with parenchymal involvement: presentation of four cases","volume":"29","author":"Shugaiv","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0460","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"29","key":"10.1016\/j.revmed.2013.12.003_bib0465","first-page":"1355","article-title":"[Value of \u00ab\u00a0bolus\u00a0\u00bb cyclophosphamide injections in Beh\u00e7et's disease. Experience of 17\u00a0cases]","volume":"19","author":"Du","year":"1990","journal-title":"Presse Med"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0470","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et's disease with sight threatening posterior or panuveitis","volume":"87","author":"K\u00f6tter","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.revmed.2013.12.003_bib0475","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0480","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0485","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","article-title":"Beh\u00e7et's syndrome: treatment with recombinant leukocyte alpha-interferon","volume":"278","author":"Tsambaos","year":"1986","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0490","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: review of the literature","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0495","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"10.1016\/j.revmed.2013.12.003_bib0500","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","article-title":"Infliximab in the treatment of posterior uveitis in Beh\u00e7et's disease. Long term follow up in four patients","volume":"34","author":"Lanthier","year":"2005","journal-title":"Presse Med"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0505","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"10.1016\/j.revmed.2013.12.003_bib0510","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3748\/wjg.14.2912","article-title":"Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment","volume":"14","author":"Sari","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.revmed.2013.12.003_bib0515","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/bjo.2007.127522","article-title":"Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon alpha","volume":"92","author":"Evereklioglu","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.revmed.2013.12.003_bib0520","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1469-0691.2007.01796.x","article-title":"Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment","volume":"13","author":"Mancini","year":"2007","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0525","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2013.12.003_bib0530","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0535","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ard.62.3.280","article-title":"Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Beh\u00e7et's syndrome","volume":"62","author":"Licata","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.revmed.2013.12.003_bib0540","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/jnnp.2004.055434","article-title":"Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Beh\u00e7et disease","volume":"76","author":"Ribi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0545","first-page":"181","article-title":"Successful treatment of long-standing neuro-Beh\u00e7et's disease with infliximab","volume":"32","author":"Sarwar","year":"2005","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0550","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2006.056804","article-title":"Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile","volume":"66","author":"Fujikawa","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"10.1016\/j.revmed.2013.12.003_bib0555","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0560","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of Neuro-Beh\u00e7et's disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0565","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et's disease?","volume":"66","author":"Van Laar","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4\u00a0Suppl. 50","key":"10.1016\/j.revmed.2013.12.003_bib0570","first-page":"S133","article-title":"Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Beh\u00e7et's disease","volume":"26","author":"Belzunegui","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0575","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A patient with neuro-Beh\u00e7et's disease is successfully treated with etanercept: further evidence for the value of TNF-alpha blockade","volume":"109","author":"Alty","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0580","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Beh\u00e7et's syndrome with chimeric tumour necrosis factor alpha antibody","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"issue":"29\u201330","key":"10.1016\/j.revmed.2013.12.003_bib0585","first-page":"414","article-title":"Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders","volume":"132","author":"Aeberli","year":"2002","journal-title":"Swiss Med Wkly"},{"issue":"8","key":"10.1016\/j.revmed.2013.12.003_bib0590","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s10067-006-0410-3","article-title":"Successful treatment of life-threatening intestinal ulcer in Beh\u00e7et's disease with infliximab: rapid healing of Beh\u00e7et's ulcer with infliximab","volume":"26","author":"Ju","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0595","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3904\/kjim.2007.22.1.24","article-title":"Remission of intestinal Beh\u00e7et's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)","volume":"22","author":"Lee","year":"2007","journal-title":"Korean J Intern Med"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0600","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","article-title":"Treatment of recalcitrant orogenital ulceration of Beh\u00e7et's syndrome with infliximab","volume":"40","author":"Robertson","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.revmed.2013.12.003_bib0605","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/ard.2003.010975","article-title":"Successful treatment of genital ulcers with infliximab in Behcet's disease","volume":"63","author":"Haugeberg","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0610","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2133.2005.06914.x","article-title":"Infliximab treatment for severe orogenital ulceration in Beh\u00e7et's disease","volume":"153","author":"Connolly","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4\u00a0Suppl. 45","key":"10.1016\/j.revmed.2013.12.003_bib0615","first-page":"S99","article-title":"Infliximab for the treatment of resistant oral ulcers in Beh\u00e7et's disease: a case report and review of the literature","volume":"25","author":"Almoznino","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.revmed.2013.12.003_bib0620","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/ard.2005.045195","article-title":"Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment","volume":"65","author":"Baki","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0625","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semarthrit.2011.02.006","article-title":"Resolution of Beh\u00e7et's syndrome associated pulmonary arterial aneurysms with infliximab","volume":"41","author":"Schreiber","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"4\u00a0Suppl. 67","key":"10.1016\/j.revmed.2013.12.003_bib0630","first-page":"S94","article-title":"Infliximab for life-threatening pulmonary artery aneurysms in Beh\u00e7et's disease. A case report","volume":"29","author":"Tolosa-Vilella","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.revmed.2013.12.003_bib0635","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","article-title":"Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome","volume":"46","author":"Seyahi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.12.003_bib0640","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","author":"Mesquida","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.revmed.2013.12.003_bib0645","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":"Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beh\u00e7et disease","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"issue":"3\u00a0Suppl. 72","key":"10.1016\/j.revmed.2013.12.003_bib0650","first-page":"S62","article-title":"Switching of anti-TNF-\u03b1 agents in Beh\u00e7et's disease","volume":"30","author":"Furuta","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0655","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis","volume":"31","author":"Takase","year":"2011","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.revmed.2013.12.003_bib0660","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1157\/13083329","article-title":"[Medium-long term treatment with infliximab and methotrexate in posterior and\/or chronic uveitis refractory to conventional treatment]","volume":"126","author":"Cobo-Ib\u00e1\u00f1ez","year":"2006","journal-title":"Med Clin (Barc)"},{"issue":"10","key":"10.1016\/j.revmed.2013.12.003_bib0665","first-page":"1428","article-title":"Production of TNF-alpha and IL-1\u00a0in active Beh\u00e7et's disease","volume":"17","author":"Hamzaoui","year":"1990","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.revmed.2013.12.003_bib0670","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","article-title":"Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease","volume":"71","author":"Ugurlu","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3\u00a0Suppl. 72","key":"10.1016\/j.revmed.2013.12.003_bib0675","first-page":"S115","article-title":"Successful use of canakinumab in a patient with resistant Beh\u00e7et's disease","volume":"30","author":"Cantarini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.revmed.2013.12.003_bib0680","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Beh\u00e7et's disease patients. Relationship with disease activity","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2013.12.003_bib0685","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6\u00a0in neuro-Beh\u00e7et's disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.revmed.2013.12.003_bib0690","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313011363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313011363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:32:38Z","timestamp":1759336358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866313011363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":138,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0248866313011363"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2013.12.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement de la maladie de Beh\u00e7et","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2013.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}